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1  | INTRODUC TION
Frailty is a physical syndrome manifest by distinct vulnerability to 
stressors as the deterioration in physiologic reserve.1 The Fried 
physical frailty phenotype is characterized by weakness, low energy, 
unintentional weight loss, slowed gait, and low physical activity.1 
Although the physical frailty phenotype was initially identified as 
a risk factor for adverse outcomes in community- dwelling older 
adults, it has since been identified as an important predictor of ad-
verse outcomes in individuals with end- stage renal disease (ESRD) 
as well.2-5 For instance, an estimated 20% of kidney transplant (KT) 
recipients exhibited frailty at KT admission,6 and the clinical phe-
notype is a predictor of adverse short- and long- term post- KT out-
comes such as longer length of hospital stay, delayed graft function, 
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Abstract
Depressive symptoms and frailty are each independently associated with morbidity 
and mortality in kidney transplant (KT) recipients. We hypothesized that having both 
depressive symptoms and frailty would be synergistic and worse than the independ-
ent effect of each. In a multicenter cohort study of 773 KT recipients, we measured 
the Fried frailty phenotype and the modified 18- question Center for Epidemiologic 
Studies- Depression Scale (CES- D). Using adjusted Poisson regression and survival 
analysis, we tested whether depressive symptoms (CES- D score > 14) and frailty 
were associated with KT length of stay (LOS), death- censored graft failure (DCGF), 
and mortality. At KT admission, 10.0% of patients exhibited depressive symptoms, 
16.3% were frail, and 3.6% had both. Recipients with depressive symptoms were 
more likely to be frail (aOR = 3.97, 95% CI: 2.28- 6.91, P < 0.001). Recipients with 
both depressive symptoms and frailty had a 1.88 times (95% CI: 1.70- 2.08, P < 0.001) 
longer LOS, 6.20- fold (95% CI:1.67- 22.95, P < 0.01) increased risk of DCGF, and 2.62- 
fold (95% CI:1.03- 6.70, P = 0.04) increased risk of mortality, compared to those who 
were nonfrail and without depressive symptoms. There was only evidence of syner-
gistic effect of frailty and depressive symptoms on length of stay (P for interac-
tion < 0.001). Interventions aimed at reducing pre- KT depressive symptoms and 
frailty should be explored for their impact on post- KT outcomes.
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worse health- related quality of life, early hospital readmission, immuno-
suppression intolerance, and mortality.6-12 While previous studies have 
demonstrated that physical frailty and depressive symptoms commonly 
co- occur leading to adverse outcomes,13 the impact of this physical frailty 
phenotype on adverse KT outcomes among patients with and without 
mental health vulnerabilities, like depressive symptoms, is unclear.
Symptoms of depression include the frailty components of 
weight loss, low energy, and decreased physical activity.1,14 Among 
KT recipients, 18%- 22% have depressive symptoms post- KT.15-17 
These depressive symptoms are important markers of vulnerability 
and are independently associated with adverse outcomes after KT, 
including medication nonadherence, return to dialysis therapy, graft 
failure, as well as cardiovascular and all- cause mortality.15,18-22 Given 
that frail community- dwelling older adults with concurrent depres-
sion are more vulnerable to adverse outcomes,13 we hypothesized 
that depressive symptoms and frailty may have a synergistic associa-
tion with adverse post- KT outcomes like length of stay, an important 
driver of subsequent mortality.7
We hypothesized that the presence of physical vulnerability cap-
tured by frailty status and mental health vulnerability measured by 
depressive symptoms synergistically impacts adverse KT outcomes. 
Using a prospective, multicenter cohort of KT recipients, the goals 
of this study were to estimate the prevalence of the co- occurrence 
of depressive symptoms and frailty at admission for KT, charac-
terize the differences in depressive symptoms between frail and 
nonfrail recipients, and quantify the association between their co- 
occurrence and adverse outcomes after KT including length of stay 
(LOS), death- censored graft failure (DCGF), and mortality.
2  | MATERIAL S AND METHODS
2.1 | Study population
This was a multicenter, prospective, longitudinal study of 773 adult 
(age 18 years and older) first- time KT recipients at the Johns Hopkins 
Hospital (N = 707) and the University of Michigan University Hospital 
(N = 66), from August 2009 to September 2017. KT candidates were 
enrolled at admission for KT, and the only inclusion criteria were 
speaking English; of those screened, <5% of all KTs did not meet this 
inclusion criteria. For the current analysis, we excluded participants 
who did not provide complete data on depressive symptoms (16.5%) 
or did not perform the frailty assessments (4.2%). Eligible partici-
pants who were excluded were similar to those who were included 
based on age (P = 0.86), sex (P = 0.11), and donor type (P = 0.34).
In this study, we measured the Fried physical frailty pheno-
type and Center for Epidemiologic Studies- Depression Scale 
(CES- D) at admission for KT as described below; these assess-
ments were conducted as part of a research protocol for the co-
hort study. Recipient, donor, and transplant factors (age, sex, 
race, body mass index [BMI], time on dialysis, causes of ESRD, 
and donor type [living donor vs deceased donor]) were abstracted 
from	medical	charts.	Obesity	was	 defined	 as	 a	BMI	 of	 ≥30	kg/m2. 
A modified Charlson comorbidity index (mCCI) adapted for pa-
tients with ESRD was calculated based on both abstracted and self- 
reported comorbidities at the time of admission for KT.23 The Johns 
Hopkins Institutional Review Board and the University of Michigan 
Institutional Board approved the study, and all participants provided 
written informed consent. This research is in adherence with the 
Declaration of Helsinki.
2.2 | Frailty measurement
We assessed frailty at KT admission using the Fried frailty phe-
notype, a measure of physiologic reserve based on 5 compo-
nents: slowed gait speed (walking time of 15 feet below an 
established cutoff by gender and height), weakness (grip strength 
below an established cutoff based on gender and BMI), exhaus-
tion (self- report using two items from the CES- D), shrinking (self- 
report of unintentional weight loss of more than 10 pounds in the 
past year based on estimated “dry weight”), and low physical activ-
ity (kcal expended/wk below an established cutoff).1 Each of the 
five components was scored as either a 0 or 1 based on its absence 
or presence, respectively. The aggregate frailty score was calculated 
as the sum of the components on a scale from 0 to 5, with scores 
≥3	categorized	as	frail.	This	scoring	has	previously	been	validated	in	
older adults and in ESRD and KT populations.3,6-9,11,12,24-28
2.3 | Depressive symptoms measurement
We ascertained depressive symptoms at KT admission using the 
CES- D, a 20- item questionnaire that queries depressive symptoms 
over the past week.14 Responses to each of the 20 questions are 
scored as a 0, 1, 2, or 3. This instrument has been previously vali-
dated in patients with ESRD 29-32 and identifies symptoms in the 
areas of depressed mood, guilt/worthlessness, helplessness/hope-
lessness, psychomotor retardation, loss of appetite, and sleep distur-
bance.	The	scale	ranges	from	0	to	60,	with	a	score	of	≥16	indicating	
depressive symptoms. In the analysis, we excluded two questions 
that overlapped with the exhaustion component of the Fried frailty 
phenotype (“Did you feel that everything you did was an effort?” and 
“Could you not get ‘going’?”). We modified the cutoff score to reflect 
the 2 omitted questions, resulting in a new depressive symptoms 
cutoff score of >14 out of a possible 54.
2.4 | Depressive symptoms and frailty
KT recipients were categorized by their frailty/depressive symptoms 
status: (a) nonfrail/no depressive symptoms; (b) nonfrail/depressive 
symptoms; (c) frail/no depressive symptoms; or (d) frail/depressive 
symptoms. Recipient, donor, and transplant factors were summarized 
using means and standard deviations for normally distributed factors, 
medians and IQRs for non- normally distributed factors, and percent-
ages for categorical variables. We tested whether recipient, donor, 
and transplant factors differed by frailty/depressive symptoms sta-
tus using Fisher’s exact tests for categorical variables and Student t 
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tests and Wilcoxon rank sum tests for continuous factors depending 
on their distribution. The association between frailty and depressive 
symptoms was quantified using adjusted logistic regression.
2.5 | Depressive symptoms, frailty, and 
length of stay
We quantified the association between frailty/depressive symptoms 
status and LOS using a multilevel Poisson regression model [adjusted 
relative risk (aRR)] to account for the variation in LOS due to differ-
ences between the two hospitals.
2.6 | Depressive symptoms, frailty, death- censored 
graft failure, and mortality
We quantified the association between frailty/depressive symptoms 
status and DCGF as well as mortality using adjusted Cox propor-
tional hazards models. Cumulative incidences of DCGF and mortality 
were estimated using a Kaplan- Meier approach. For all models, pro-
portional hazard assumptions were confirmed by visual inspection of 
the complementary log- log plots and Schoenfeld residuals.
2.7 | Statistical analysis
Parsimonious models were adjusted for age, sex, and race. All other 
models were adjusted for age, sex, race, education, BMI, mCCI, 
causes of ESRD, time on dialysis, and donor type. As sensitivity anal-
yses, we additionally adjusted for delayed graft function (DGF) in the 
analysis with LOS as the outcome. For all analyses, a P- value of <0.05 
was considered statistically significant. All data were analyzed using 
Stata 14 (College Station, TX, USA).
3  | RESULTS
3.1 | Study population
Among 773 KT recipients, the mean age was 54 years (SD = 14 years; 
range: 19- 86), 37.8% of KT recipients were female, 40.9% were 
African American, 41.4% attained a high school education or less, 
35.3% were obese, 20.6% had diabetes, 40.8% spent >2 years on 
dialysis, and 38.0% received a live donor KT. The median Charlson 
comorbidity index score was 1 (IQR: 0- 3).
3.2 | Depressive symptoms
The median CES- D score was 4 (IQR: 1- 9). About 10.0% of KT re-
cipients had depressive symptoms (77 recipients). KT recipients with 
depressive symptoms were younger (median [IQR]: 50.0 [40.8, 58.7] 
vs 57.7 [45.9, 65.8], P < 0.001) and more likely to be female (53.3% 
vs 36.1%, P = 0.003; Table S5). There were no significant differences 
in BMI, cause of ESRD, donor type, education level, or time spent on 
dialysis between KT recipients with and without depressive symp-
toms (Figure 1).
3.3 | Depressive symptoms and frailty
About 3.6% (28 recipients) of KT recipients exhibited both frailty 
and depressive symptoms (Table 1). The median CES- D score was 
4 (IQR: 2- 9) among nonfrail recipients and 8 (IQR: 4- 16) among 
frail recipients. Additionally, CES- D scores increased monotoni-
cally with increasing frailty score (Figure 2). KT recipients who 
were frail and had depressive symptoms were more likely to be 
female (60.7% vs 35.8%, P = 0.02) and have a high school educa-
tion or below (53.4% vs 37.6%, P = 0.02) compared to nonfrail KT 
recipients without depressive symptoms (Table 1). There were 
no differences in delayed graft function rates between the four 
frailty- depressive symptoms groups (P = 0.72). Depressive symp-
toms were independently associated with frailty (aOR = 3.97, 
95% CI:2.28- 6.91, P < 0.001). Further, frail KT recipients were 
more likely than nonfrail KT recipients to report 9 of 18 depres-
sive symptoms including inattention (30.2% vs 13.8%, P < 0.001), 
depressed mood (18.3% vs 5.1%, P < 0.001), and loss of appetite 
(23.8% vs 14.2%, P = 0.01; Table 2).
3.4 | Depressive symptoms, frailty, and 
length of stay
The median LOS was 10 days (IQR: 6- 12). After adjusting for re-
cipient, donor, and transplant factors, KT recipients with depressive 
symptoms who were concurrently frail had a 1.88 times (95% CI: 
1.70- 2.08) longer LOS; KT recipients with depressive symptoms but 
not frail had a 1.38 times (1.27- 1.52) longer LOS. The co- occurrence 
of depressive symptoms and frailty had a synergistic effect on longer 
F IGURE  1 Prevalence and overlap of depressive symptoms, 
frailty, and comorbidity at the time of kidney transplantation 
(N = 773). The Fried frailty phenotype is scored on a scale ranging 
from	0	to	5	components,	with	the	presence	of	≥3	components	
representing frailty. Depressive symptoms were assessed using 
the modified CES- D, in which questions about exhaustion were 
removed to avoid overlap with the Fried frailty phenotype. The 
modified CES- D is scored on a scale from 0 to 54, with scores >14 
indicating depressive symptoms. Comorbidity was defined as a 
score	of	≥2	diseases	on	the	modified	Charlson	comorbidity	index	
for ESRD and KT recipients
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TABLE  1 Characteristics of kidney transplant recipients, by depressive symptoms and frailty status (N = 773)
No depressive symptoms, 
nonfrail (n = 598)
Depressive symptoms, 
nonfrail (n = 49)
No depressive symptoms, 
frail (n = 98)
Depressive symptoms, 
frail (n = 28)
Age, median (IQR) 56.6 (44.9- 65.1) 49.0 (40.8- 55.7) 60.3 (51.3- 68.3) 53.4 (35.6- 61.8)
Female, % 35.8 49.0 37.8 60.7
African American, 
%
39.5 36.7 51.0 42.9
Education level, %
	≤High	school 37.6 44.9 52.0 53.4
BMI, %
 Underweight 2.3 2.0 2.0 14.3
 Normal 29.3 24.5 24.5 25.0
 Overweight 33.3 36.7 36.7 28.6
 Obese 35.1 36.7 36.7 32.1
Cause of ESRD, %
 Hypertension 34.0 18.4 38.8 35.7
 Diabetes 21.2 18.4 18.4 17.9
 Other 44.8 63.3 42.9 46.4
Living donor 
recipient, %
39.1 44.9 28.6 35.7
Delayed graft 
function, %
22.8 20.4 27.6 25.0
mCCI, median 
(IQR)
1 (0- 3) 0 (0- 2) 2 (0- 3) 1.5 (0- 2)
Time on dialysis, %
 Pre- emptive KT 26.3 28.6 23.5 25.0
	≤2	y 32.9 24.5 24.5 21.4
 >2 y 40.8 46.9 52.0 53.6
BMI, body mass index at KT; mCCI, modified Charlson comorbidity index; ESRD, end- stage renal disease, IQR, interquartile range
F IGURE  2 Distribution of pre–kidney 
transplantation depressive symptoms 
score among frail and nonfrail kidney 
transplant recipients (N = 773). Fried 
frailty phenotype, scored on a scale 
ranging from 0 to 5 components, 
with	the	presence	of	≥3	components	
representing frailty. The modified 
CES- D is scored on a scale from 0 to 54, 
with scores >14 indicating depressive 
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LOS (P for interaction < 0.001; Table 3). Among nonfrail KT recipi-
ents, each 10- point increase in the CES- D score was associated with 
1.17 times (95% CI: 1.27- 1.52) longer LOS. Among frail KT recipi-
ents, each 10- point increase in the CES- D score was associated with 
1.23 times (95% CI: 1.16- 1.31) longer LOS. The association between 
increased CES- D score and longer LOS differed significantly by 
frailty status (P for interaction = 0.009; Table 3).
3.5 | Depressive symptoms, frailty, and death- 
censored graft failure
For KT recipients with depressive symptoms and frailty, DCGF at 5- years 
post- KT was 19.1%, compared to 8.5% for nonfrail KT recipients with-
out depressive symptoms (Table 4). After adjusting for recipient, donor, 
and transplant factors, KT recipients with depressive symptoms and 
frailty were at a 6.20- fold (95% CI: 1.67- 22.95, P < 0.01) increased risk of 
DCGF compared to nonfrail KT recipients without depressive symptoms 
(Table 4). The association between depressive symptoms and increased 
risk of DCGF did not differ by frailty status (P for interaction = 0.67).
3.6 | Depressive symptoms, frailty, and mortality
For KT recipients with depressive symptoms and frailty, mortality at 5- 
years post- KT was 27.5%, compared to 14.1% for nonfrail KT recipients 
without depressive symptoms. After adjusting for recipient, donor, and 
transplant factors, KT recipients with depressive symptoms and frailty 
were at a 2.62- fold (95% CI: 1.03- 6.70, P = 0.04) higher risk of mortal-
ity compared to nonfrail KT recipients without depressive symptoms 
(Table 4). The association between depressive symptoms and higher 
risk of mortality did not differ by frailty status (P for interaction = 0.61).
4  | DISCUSSION
In this prospective, multicenter study of 773 KT recipients, 10.0% 
of KT recipients had depressive symptoms and 16.3% of KT recipi-
ents were frail. We found that the presence of depressive symptoms 
was associated with a 3.97- fold higher likelihood of being frail. The 
co- occurrence of depressive symptoms and frailty was observed 
in 3.6% of KT recipients and was associated with a synergistically 
longer length of stay. Additionally, frail recipients who had depres-
sive symptoms experienced a 6.20- fold increased risk of DCGF and a 
2.62- fold increased risk of mortality, compared to KT recipients who 
were not frail and did not exhibit depressive symptoms. However, 
we did not find a synergistic effect between frailty and depressive 
symptoms on the longer- term outcomes of DCGF and mortality.
Our finding of depressive symptoms among 10% of KT recipients 
was lower than previously reported estimates of 21%- 27% among 
nondialysis chronic kidney disease 33 and 26% among maintenance 
hemodialysis patients.34 The prevalence of depressive symptoms 
is likely lower in KT recipients because these patients complete 
an extensive mental health screening prior to clearance for KT. 
Additionally, we found KT recipients who were younger, female, and 
frail were more likely to have depressive symptoms. This is consis-
tent with a study of post- KT Medicare claims which reported higher 
rates of diagnosed depression among female and younger KT recipi-
ents.21 Notably, we report the novel finding of increased depressive 
symptoms reported among frail KT recipients, suggesting that frail 
TABLE  2 Depressive symptoms reported by frail and nonfrail 




(n = 647) Frail (n = 126) P- value
Responding “Occasionally” or “Most of the Time,” (%)
Were you bothered by 
things that usually 
don’t bother you?
10.1 13.5 0.3
Did you not feel like 
eating; your appetite 
was poor?
14.2 23.8 0.01
Did you feel that you 
could not shake off 
the blues?
4.0 12.7 <0.001
Did you feel people 
were unfriendly?
7.6 10.3 0.2
Did you have trouble 
keeping your mind on 
what you were doing?
13.8 30.2 <0.001
Did you feel 
depressed?
5.1 18.3 <0.001
Did you feel sad? 4.6 15.9 <0.001
Did you think your life 
had been a failure?
1.7 6.4 0.01
Did you feel fearful? 6.2 14.3 0.01
Was your sleep 
restless?
32.6 41.3 0.07
Did you have crying 
spells?
3.9 4.8 0.08
Did you talk less than 
usual?
8.0 14.3 0.04
Did you feel that 
people disliked you?
1.4 2.4 0.4
Did you feel lonely? 5.1 12.7 0.004
Responding “Rarely” or “Some of the Time,” a(%)
Did you feel you were 
just as good as other 
people?
7.6 10.3 0.3
Did you enjoy your life? 3.3 2.4 0.8
Were you happy? 3.9 4.8 0.6
Did you feel hopeful 
about the future?
1.7 6.4 <0.001
Row percentages are reported. The modified CES- D is an 18- item ques-
tionnaire that queries depressive symptoms from over the past week. 
Possible responses to the questions are “Rarely or none of the time,” 
“Some or a little of the time,” “Occasionally or a moderate amount of the 
time,” and “Most or all of the time.”
aResponses were inversely scaled when calculating the total CES- D 
score. 
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recipients are not only physically vulnerable but often experience 
comorbid depressive symptoms, which likely puts them on an accel-
erated path to adverse health outcomes.
We have extended previous findings of a 4%- 16% co- occurrence 
of depressive symptoms and frailty among community- dwelling 
older adults to a surgical population of KT recipients and report a 
slightly lower prevalence.13,35-38 Additionally, the co- occurrence of 
depressive symptoms and frailty was observed in KT recipients of 
all ages, but was most common in those who were younger, female, 
and had less than a high school education. Importantly, the co- 
occurrence of depressive symptoms and frailty was associated with 
significantly increased risk of DCGF and mortality, but we did not 
observe a synergistic effect of the two conditions on these long- 
term outcomes potentially due to a lack of power.
Prior prospective studies have identified frailty as a predictor of 
longer LOS7; however, our study is the first to show a similar impact of 
pre- KT depressive symptoms on LOS. Our finding of a 1.38 times lon-
ger LOS among KT recipients with depressive symptoms is consistent 
TABLE  4 Cumulative incidence and risk of death- censored graft failure and mortality among kidney transplant recipients, by depressive 
symptoms and frailty status (N = 773)
1- y 3- y 5- y
aHR (95% CI)
P- value for 
interactionParsimonious model Fully adjusted model
Death- censored graft failure
 No depressive symptoms, 
Nonfrail
1.3 4.4 8.5 Ref Ref
 Depressive symptoms, 
Nonfrail
6.8 6.8 6.8 2.17 (0.65, 7.23) 3.16 (0.90, 11.04)
 No depressive symptoms, 
Frail
1.1 6.1 8.7 1.14 (0.47, 2.77) 0.97 (0.37, 2.75)
 Depressive symptoms, Frail 0 19.1 19.1 4.26 (1.23, 14.80) 6.20 (1.67, 22.95) 0.67
 CES- D score (10- point 
increase)
1.69 (1.04, 2.77) 1.86 (1.10, 3.14) 0.28
Mortality
 No depressive Symptoms, 
Nonfrail
3.6 10.7 14.1 Ref Ref
 Depressive Symptoms, 
Nonfrail
4.6 11.4 20.2 1.57 (0.57, 4.36) 1.92 (0.68, 5.38)
 No depressive Symptoms, 
Frail
4.2 11.7 16.1 0.90 (0.49, 1.64) 0.93 (0.49, 1.76)
 Depressive Symptoms, Frail 3.7 9.4 27.5 2.51 (1.00, 6.31) 2.62 (1.03, 6.70) 0.61
 CES- D score (10- point 
increase)
1.51 (1.06, 2.17) 1.45 (0.98, 2.14) 0.82
Cumulative incidences are expressed as % and estimated using a Kaplan- Meier approach. All Cox proportional hazards models were adjusted for age, 
sex, race, education, BMI, cause of ESRD, time on dialysis, modified Charlson comorbidity index, and donor type.
TABLE  3 Length of stay among kidney transplant recipients with depressive symptoms, by frailty status (N = 773)
Median days (IQR)
Length of Stay 
aRR (95% CI)
P- value for interactionParsimonious model Fully adjusted model
Depressive symptoms
 Nonfrail 10 (7- 14) 1.38 (1.27, 1.52) 1.38 (1.27, 1.52)
 Frail 10 (7- 16) 1.85 (1.67, 2.05) 1.88 (1.70, 2.08) <0.001
CES- D Score (10- point increase)
 Nonfrail 1.11 (1.06, 1.16) 1.17 (1.08, 1.27)
 Frail 1.22 (1.15, 2.29) 1.23 (1.16, 1.31) 0.009
The parsimonious models were adjusted for age, sex, and race. The fully adjusted models were adjusted for age, sex, race, education, BMI, cause of 
ESRD, time on dialysis, modified Charlson comorbidity index, and donor type. Additionally, the P- values for the interactions were based on the fully 
adjusted models.
     |  7 of 8KONEL Et aL.
with a previous report of a 1.25 times longer LOS among liver trans-
plant recipients with pre–liver transplant depressive symptoms.39 This 
finding suggests a significant impact of pre- KT depressive symptoms 
on immediate perioperative outcomes. We also found that the pres-
ence of both frailty and depressive symptoms at KT admission syner-
gistically increased LOS.
This study has several important strengths including prospective 
measurement of depressive symptoms as well as frailty ascertained 
at KT admission in a large multicenter cohort study. To assess depres-
sive symptoms, we used the CES- D based on the screening tool’s val-
idation for use in ESRD patients and ease of administration.29-32 The 
CES- D tool’s wide use also allows direct comparison with studies of 
the relationship between frailty and depressive symptoms among 
older adults and other chronic illness populations. To avoid measur-
ing the same exposures, the overlapping exhaustion component be-
tween the CES- D and the Fried frailty phenotype was mitigated by 
omitting the two exhaustion questions from the total CES- D score.38 
Additionally, the CES- D may have utility in clinical settings by allow-
ing transplant centers to monitor psychological symptoms outside 
of a formal diagnosis of depression, as well as identify KT recipients 
with more mild depressive symptoms. However, our study does have 
some limitations. Although this study sample included over 700 KT 
recipients, insufficient power may have hindered our ability to detect 
all interactions of frailty and depressive symptom as well as some of 
the marginal effects (ie, for those with no depressive symptoms and 
frailty) with adverse post- KT outcomes. While we did not enroll all 
KT recipients at these centers, our response rate was approximately 
65%. It is unlikely that there was a selection bias because the cohort 
was representative of the KT population at these centers, and there 
are no systematic differences in those who were enrolled and not en-
rolled that would distort the associations between depressive symp-
toms, frailty, and these adverse outcomes. Furthermore, participants 
reported their depressive symptoms in the prior 2 weeks at admission 
for KT and there may be recall bias at this time. Additionally, there was 
no information on the use of antidepressants in this cohort. Finally, 
the cross- sectional ascertainment of frailty and depressive symptoms 
prohibits examination of temporality between the onset of depressive 
symptoms and development of frailty.
In conclusion, the co- occurrence of depressive symptoms and 
frailty was associated with a synergistically longer length of hospital 
stay, as well as an increased risk of DCGF and mortality. However, the 
synergistic effect of frailty and depressive symptoms only impacts 
short- term outcomes like LOS; frailty and depressive are both, sep-
arately, associated with long- term outcomes but do not have a syn-
ergistic effect long term. Our study provides preliminary evidence 
for a critical need of pre- KT screening for both depressive symptoms 
and frailty to better identify KT candidates at higher risk for adverse 
post- KT outcomes. Given the elevated risk of adverse outcomes 
among frail KT recipients with depressive symptoms, consideration 
of the overlap of physical and mental health vulnerabilities may be an 
important aspect of care for this patient population. Depressive symp-
toms and frailty assessment at KT admission may have the potential 
to identify KT recipients at higher risk of adverse outcomes and may 
also provide further insights into the mechanisms leading to these ad-
verse outcomes. Exploring interventions aimed at reducing the burden 
of both depressive symptoms and frailty, such as pre- habilitation pro-
grams, may be warranted in order to improve post- KT outcomes.
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